IL151373A0 - Pharmaceutical compositions for treating cancer comprising a 1,4-benzodiazepine derivative - Google Patents
Pharmaceutical compositions for treating cancer comprising a 1,4-benzodiazepine derivativeInfo
- Publication number
- IL151373A0 IL151373A0 IL15137301A IL15137301A IL151373A0 IL 151373 A0 IL151373 A0 IL 151373A0 IL 15137301 A IL15137301 A IL 15137301A IL 15137301 A IL15137301 A IL 15137301A IL 151373 A0 IL151373 A0 IL 151373A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- treating cancer
- benzodiazepine derivative
- benzodiazepine
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19227800P | 2000-03-27 | 2000-03-27 | |
PCT/US2001/009193 WO2001072721A2 (en) | 2000-03-27 | 2001-03-22 | Synergistic methods and compositions for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL151373A0 true IL151373A0 (en) | 2003-04-10 |
Family
ID=22709017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15137301A IL151373A0 (en) | 2000-03-27 | 2001-03-22 | Pharmaceutical compositions for treating cancer comprising a 1,4-benzodiazepine derivative |
Country Status (24)
Country | Link |
---|---|
US (1) | US6537988B2 (xx) |
EP (1) | EP1272193B1 (xx) |
JP (1) | JP5110756B2 (xx) |
KR (1) | KR20020084254A (xx) |
CN (1) | CN100384424C (xx) |
AR (1) | AR028296A1 (xx) |
AT (1) | ATE430570T1 (xx) |
AU (2) | AU4768301A (xx) |
BR (1) | BR0109517A (xx) |
CA (1) | CA2404712A1 (xx) |
CZ (1) | CZ20023220A3 (xx) |
DE (1) | DE60138611D1 (xx) |
ES (1) | ES2325055T3 (xx) |
HU (1) | HUP0301690A3 (xx) |
IL (1) | IL151373A0 (xx) |
MX (1) | MXPA02009463A (xx) |
MY (1) | MY127082A (xx) |
NO (1) | NO20024610L (xx) |
PE (1) | PE20011291A1 (xx) |
RU (1) | RU2264217C2 (xx) |
TW (1) | TWI310684B (xx) |
UY (1) | UY26635A1 (xx) |
WO (1) | WO2001072721A2 (xx) |
ZA (1) | ZA200207766B (xx) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ335383A (en) | 1996-11-18 | 2000-10-27 | Biotechnolog Forschung Gmbh | Epothilone C,D,E and F for plant protection and cytostatic effects shown in kidney cells |
DE69734362T2 (de) | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
US6867305B2 (en) * | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
AU2002211427A1 (en) * | 2000-10-05 | 2002-04-15 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
WO2002032400A1 (en) * | 2000-10-16 | 2002-04-25 | Neopharm, Inc. | Liposomal formulation of mitoxantrone |
US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
US7037906B1 (en) * | 2000-12-22 | 2006-05-02 | Oxigene, Inc. | Methods for modulating tumor growth and metastasis |
JP2004529904A (ja) * | 2001-03-14 | 2004-09-30 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ |
MXPA03010401A (es) * | 2001-05-16 | 2004-03-09 | Novartis Ag | Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico. |
WO2003035047A2 (en) * | 2001-10-25 | 2003-05-01 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
AU2002359412A1 (en) * | 2001-11-13 | 2003-05-26 | Bristol-Myers Squibb Company | Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds |
TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
WO2003053350A2 (en) * | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
US20030147813A1 (en) * | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
CN1652845A (zh) * | 2002-05-17 | 2005-08-10 | 安万特医药股份有限公司 | 多西他赛/阿霉素/环磷酰胺在辅助治疗乳腺癌和卵巢癌中的用途 |
KR101086533B1 (ko) * | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
US6627614B1 (en) * | 2002-06-05 | 2003-09-30 | Super Gen, Inc. | Sequential therapy comprising a 20(S)-camptothecin and an anthracycline |
MXPA04012444A (es) * | 2002-06-10 | 2005-04-19 | Novartis Ag | Combinaciones que comprenden epotilonas y sus usos farmaceuticos. |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
SI1767535T1 (sl) * | 2002-08-23 | 2010-03-31 | Sloan Kettering Inst Cancer | Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh |
US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
CA2525987A1 (en) * | 2003-06-05 | 2005-01-06 | Charles Achkar | Methods of treating hyperproliferative cell disorders |
EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
BRPI0413977A (pt) * | 2003-08-27 | 2006-11-07 | Osi Eyetech Inc | método para suprimir um distúrbio neovascular, e para tratar um paciente diagnosticado com ou em risco de desenvolver um distúrbio neovascular, composição farmacêutica, e, embalagem farmacêutica |
ATE514783T1 (de) | 2003-11-12 | 2011-07-15 | Schering Corp | Plasmidsystem zur expression mehrerer gene |
WO2005046665A1 (en) * | 2003-11-13 | 2005-05-26 | Warner-Lambert Company Llc | Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor |
TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
US7612071B2 (en) * | 2004-03-12 | 2009-11-03 | Syntrix Biosystems, Inc. | Compositions and methods employing aminopterin |
EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | TREATMENT OF SYNUCLEINOPATHIES |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
US20050272068A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | UCH-L1 expression and cancer therapy |
US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
JP2007529555A (ja) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド | シヌクレイノパチーを治療する方法 |
GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
MXPA06010755A (es) * | 2004-03-23 | 2006-12-15 | Astrazeneca Ab | Terapia de combinacion. |
CA2562711C (en) | 2004-04-15 | 2013-09-17 | Genencor International, Inc. | Cab molecules |
US7449196B2 (en) * | 2004-07-09 | 2008-11-11 | Robert Sabin | Anti tumor compositions and methods of use |
GB0419071D0 (en) | 2004-08-26 | 2004-09-29 | Mgx Internat Ltd | Display device |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
JP2008521907A (ja) * | 2004-12-03 | 2008-06-26 | シェーリング コーポレイション | 抗igf1r治療について患者を予め選択するためのバイオマーカー |
PL1839662T3 (pl) * | 2005-01-19 | 2010-08-31 | Zeria Pharm Co Ltd | Środek przeciwnowotworowy |
CN102886045A (zh) | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
EP1856255A4 (en) | 2005-02-11 | 2010-01-27 | Univ Southern California | METHODS OF EXPRESSING PROTEINS WITH DISULFIDE BRIDGES |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
AU2006236637B2 (en) * | 2005-04-15 | 2012-09-06 | Merck Sharp & Dohme Corp. | Methods and compositions for treating or preventing cancer |
US8101728B2 (en) | 2005-04-28 | 2012-01-24 | Danisco Us Inc. | TAB molecules |
AR053272A1 (es) | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
CN101287761A (zh) * | 2005-06-15 | 2008-10-15 | 先灵公司 | 抗-igf1r抗体制剂 |
FR2887454B1 (fr) * | 2005-06-28 | 2009-06-05 | Sanofi Aventis Sa | Combinaisons antitumorales contenant des derives du taxane et des sigma ligands |
EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
KR20080103996A (ko) | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Erk 억제제로서 피롤리딘 유도체 |
US8044033B2 (en) * | 2006-03-02 | 2011-10-25 | The Board Of Regents Of The University Of Texas System | Fluorocytidine derivatives and COX-2 inhibitors for the treatment of cancer |
WO2007130501A2 (en) * | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
US20080081051A1 (en) * | 2006-09-28 | 2008-04-03 | Robert Sabin | Method of manufacturing anti-tumor and anti-viral compositions |
US20080085881A1 (en) * | 2006-10-06 | 2008-04-10 | Aimery De Gramont | Stop-and-go oxaliplatin treatment regimens |
WO2008065409A2 (en) * | 2006-12-01 | 2008-06-05 | Betagenon Ab | Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor |
AU2008222592B2 (en) * | 2007-03-02 | 2013-09-26 | Detsamma Investments Pty Ltd | Compositions and methods for delivery of anti-cancer agents |
US20100111874A1 (en) * | 2007-03-19 | 2010-05-06 | University Of Medicine And Dentistry Of New Jresey | Method of cancer detection and treatment |
CA2698944C (en) | 2007-09-10 | 2015-06-16 | Curis, Inc. | Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety |
WO2009033204A1 (en) * | 2007-09-12 | 2009-03-19 | University Of Wollongong | Multi-component compositions and methods for delivery of anti-cancer agents |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
DK2082745T3 (da) | 2007-12-28 | 2013-03-25 | Deutsches Krebsforsch | Kræftterapi med en parvovirus kombineret med kemoterapi |
CA2713571C (en) * | 2008-01-28 | 2015-06-16 | Nanocarrier Co., Ltd. | Pharmaceutical composition or combination drug |
RU2525389C2 (ru) | 2008-02-21 | 2014-08-10 | Мерк Шарп И Доум Корп. | Соединения, которые являются ингибиторами erk |
WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
US20110182888A1 (en) * | 2008-04-08 | 2011-07-28 | Peter Ordentlich | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
PL2310011T3 (pl) | 2008-06-17 | 2013-12-31 | Wyeth Llc | Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine |
AU2009313927A1 (en) * | 2008-11-13 | 2010-05-20 | Astrazeneca Ab | Azaquinolinone derivatives and uses thereof |
WO2010056901A2 (en) | 2008-11-13 | 2010-05-20 | University Of Southern California | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
KR20170113683A (ko) * | 2008-11-28 | 2017-10-12 | 노파르티스 아게 | 피리도〔4,3-d〕피리미딘 유래의 hsp90-억제제 및 her2 억제제를 포함하는 제약 조합물 |
WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EA035193B1 (ru) | 2010-05-18 | 2020-05-14 | Серулин Фарма Инк. | Композиции и способы лечения аутоиммунных и других заболеваний |
PT2500036E (pt) * | 2011-03-18 | 2014-08-25 | Metheresis Translational Res Sa | Inibidores met para aumentar a eficácia da radioterapia |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CN103374000B (zh) * | 2012-04-13 | 2015-11-11 | 中国科学院广州生物医药与健康研究院 | 嘧啶并二氮杂卓类化合物及其药用组合物和应用 |
EP3628373A1 (en) | 2013-07-12 | 2020-04-01 | IVERIC bio, Inc. | Methods for treating or preventing opthalmological conditions |
CN107043456B (zh) * | 2017-04-19 | 2019-05-17 | 川北医学院 | 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用 |
JP7352473B2 (ja) | 2017-06-21 | 2023-09-28 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | がん細胞を標的化するキメラ抗原受容体のための方法および組成物 |
US11068254B1 (en) | 2020-06-10 | 2021-07-20 | Cigna Intellectual Property, Inc. | Systems and methods for generating and managing domain-based technology architecture |
AU2022285754A1 (en) * | 2021-06-03 | 2023-12-14 | University Of Cincinnati | Bzd-1 as a chemosensitizer of cancer |
CN115814076A (zh) * | 2021-07-01 | 2023-03-21 | 江苏先声药业有限公司 | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |
US11879010B2 (en) | 2021-09-30 | 2024-01-23 | The Charlotte Mecklenburg Hospital Authority | Methods and compositions for pretargeted immunotherapy |
CN114712377B (zh) * | 2022-04-26 | 2023-08-15 | 江苏师范大学 | 断血流皂苷a在制造药物中的用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
DE19706584C2 (de) * | 1997-02-21 | 2002-09-26 | Aeg Energietechnik Gmbh | Hochtemperaturbrennstoffzellen mit Erwärmung des Reaktionsgases |
GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
WO1999002573A1 (en) * | 1997-07-08 | 1999-01-21 | Union Carbide Chemicals & Plastics Technology Cor Poration | Method for reducing sheeting during olefin polymerization |
CA2315693C (en) | 1997-12-22 | 2010-11-30 | Schering Corporation | Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases |
RU2230062C2 (ru) * | 1999-01-21 | 2004-06-10 | Бристол-Маерс Сквибб Ко. | Комплекс ингибитора ras-фарнезилтрансферазы, композиция ингибитора ras-фарнезилтрансферазы, фармацевтическая композиция |
-
2001
- 2001-03-21 TW TW090106552A patent/TWI310684B/zh not_active IP Right Cessation
- 2001-03-22 BR BRPI0109517-0A patent/BR0109517A/pt not_active Application Discontinuation
- 2001-03-22 CA CA002404712A patent/CA2404712A1/en not_active Abandoned
- 2001-03-22 IL IL15137301A patent/IL151373A0/xx not_active IP Right Cessation
- 2001-03-22 MY MYPI20011361A patent/MY127082A/en unknown
- 2001-03-22 CN CNB018071627A patent/CN100384424C/zh not_active Expired - Fee Related
- 2001-03-22 KR KR1020027012704A patent/KR20020084254A/ko not_active Application Discontinuation
- 2001-03-22 AT AT01920653T patent/ATE430570T1/de not_active IP Right Cessation
- 2001-03-22 RU RU2002129000/14A patent/RU2264217C2/ru not_active IP Right Cessation
- 2001-03-22 MX MXPA02009463A patent/MXPA02009463A/es active IP Right Grant
- 2001-03-22 AU AU4768301A patent/AU4768301A/xx active Pending
- 2001-03-22 CZ CZ20023220A patent/CZ20023220A3/cs unknown
- 2001-03-22 HU HU0301690A patent/HUP0301690A3/hu unknown
- 2001-03-22 JP JP2001570634A patent/JP5110756B2/ja not_active Expired - Fee Related
- 2001-03-22 ES ES01920653T patent/ES2325055T3/es not_active Expired - Lifetime
- 2001-03-22 EP EP01920653A patent/EP1272193B1/en not_active Expired - Lifetime
- 2001-03-22 WO PCT/US2001/009193 patent/WO2001072721A2/en active IP Right Grant
- 2001-03-22 AU AU2001247683A patent/AU2001247683B2/en not_active Ceased
- 2001-03-22 DE DE60138611T patent/DE60138611D1/de not_active Expired - Lifetime
- 2001-03-26 US US09/817,456 patent/US6537988B2/en not_active Expired - Fee Related
- 2001-03-27 PE PE2001000286A patent/PE20011291A1/es not_active Application Discontinuation
- 2001-03-27 UY UY26635A patent/UY26635A1/es not_active Application Discontinuation
- 2001-03-27 AR ARP010101457A patent/AR028296A1/es unknown
-
2002
- 2002-09-26 ZA ZA200207766A patent/ZA200207766B/en unknown
- 2002-09-26 NO NO20024610A patent/NO20024610L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1419452A (zh) | 2003-05-21 |
WO2001072721A2 (en) | 2001-10-04 |
MY127082A (en) | 2006-11-30 |
US20020002162A1 (en) | 2002-01-03 |
CN100384424C (zh) | 2008-04-30 |
AR028296A1 (es) | 2003-04-30 |
RU2002129000A (ru) | 2004-03-27 |
PE20011291A1 (es) | 2002-01-13 |
US6537988B2 (en) | 2003-03-25 |
ZA200207766B (en) | 2003-01-20 |
BR0109517A (pt) | 2006-08-29 |
NO20024610D0 (no) | 2002-09-26 |
AU4768301A (en) | 2001-10-08 |
ES2325055T3 (es) | 2009-08-25 |
DE60138611D1 (de) | 2009-06-18 |
CZ20023220A3 (cs) | 2003-11-12 |
KR20020084254A (ko) | 2002-11-04 |
HUP0301690A3 (en) | 2005-05-30 |
TWI310684B (en) | 2009-06-11 |
HUP0301690A2 (hu) | 2003-08-28 |
UY26635A1 (es) | 2001-10-25 |
JP2003528864A (ja) | 2003-09-30 |
EP1272193B1 (en) | 2009-05-06 |
RU2264217C2 (ru) | 2005-11-20 |
JP5110756B2 (ja) | 2012-12-26 |
ATE430570T1 (de) | 2009-05-15 |
EP1272193A2 (en) | 2003-01-08 |
WO2001072721A3 (en) | 2002-06-13 |
NO20024610L (no) | 2002-11-25 |
AU2001247683B2 (en) | 2006-01-12 |
MXPA02009463A (es) | 2003-04-10 |
CA2404712A1 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL151373A0 (en) | Pharmaceutical compositions for treating cancer comprising a 1,4-benzodiazepine derivative | |
ZA200003998B (en) | Pharmaceutical compositions. | |
MXPA03000771A (es) | Nuevas composiciones farmaceuticas. | |
IL152659A0 (en) | Pharmaceutical composition | |
HK1075889A1 (en) | Pharmaceutical composition | |
AU6219601A (en) | Pharmaceutical compositions | |
HUP0204555A3 (en) | Pharmaceutical composition | |
GB0009584D0 (en) | Pharmaceutical compositions | |
EP1277472A4 (en) | REMEDIES AGAINST CANCER | |
ZA200210359B (en) | Pharmaceutical compositions. | |
PL362172A1 (en) | Medicinal compositions having improved absorbability | |
PL345332A1 (en) | A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom | |
GB0031084D0 (en) | Pharmaceutical compounds | |
AU2000272858A1 (en) | Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments | |
MXPA03002105A (es) | Composiciones farmaceuticas. | |
GB0008485D0 (en) | Pharmaceutical compositions | |
GB0009613D0 (en) | Pharmaceutical compositions | |
GB0024318D0 (en) | Pharmaceutical compounds | |
IL154202A0 (en) | Pharmaceutical compositions for treating anorectal disorders | |
GB0005382D0 (en) | Pharmaceutical composition | |
HU9902296D0 (en) | Pharmaceutical composition for treating caltification | |
GB0005366D0 (en) | Pharmaceutical compounds | |
GB0101094D0 (en) | Pharmaceutical composition | |
GB0002691D0 (en) | Pharmaceutical composition | |
HRPK20020201B1 (en) | Pharmaceutical compositions for treating psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |